Regeneron Net Worth (Updated 2026).
Regeneron Pharmaceuticals, Inc., was founded in 1988 by Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos, two passionate scientists with a vision to develop transformative medicines. The company’s journey began in a small laboratory in Tarrytown, New York, where the co-founders, driven by their shared commitment to scientific innovation, set out to pioneer new approaches to treating diseases.
Regeneron’s breakthrough came in the late 1990s with the development of its proprietary technology, the VelocImmune® platform. This innovative system uses VelocImmune mice to generate fully human antibodies, a significant advancement in the field of biopharmaceuticals. The platform’s success led to the creation of several blockbuster drugs, including EYLEA® for wet age-related macular degeneration and Dupixent® for moderate-to-severe eczema and asthma, establishing Regeneron as a leader in the biotechnology industry.
Table Of Contents
Regeneron’s Current Net Worth (2025)
As of 2025, Regeneron Pharmaceuticals, Inc. has an estimated net worth of approximately $65 billion. This significant valuation reflects the company’s robust financial performance and innovative contributions to the biotechnology industry.
Career
Founded in 1988, Regeneron has grown from a small startup to a leading biotechnology company. It’s best known for developing and commercializing innovative medicines, including EYLEA for eye diseases and Dupixent for atopic dermatitis. The company employs over 10,000 people worldwide and is headquartered in Tarrytown, New York.
Other Ventures
Regeneron’s primary focus is on biotechnology, but it also has interests in other areas. It has a significant investment in Intellia Therapeutics, a company specializing in CRISPR-based therapies. Additionally, Regeneron has a collaboration with Sanofi to develop and market several of its products.
Assets
Regeneron’s assets include its extensive intellectual property portfolio, comprising over 1,000 patents and patent applications. It also owns and operates several manufacturing facilities, research and development centers, and a state-of-the-art clinical trial site. The company’s substantial cash and investments further contribute to its total assets.
Annual Income
In 2021, Regeneron reported total revenue of $24.5 billion, a significant increase from the previous year. This growth can be attributed to the strong performance of the company’s key products, including EYLEA and Dupixent. The company’s annual income has been consistently growing, reflecting its successful business strategy and innovative pipeline.
Frequently Asked Questions about Regeneron
Frequently Asked Questions about Regeneron
1. What is Regeneron’s net worth?
Regeneron’s net worth is estimated to be around $65 billion.
2. What does Regeneron do?
Regeneron is a biotechnology company that discovers, develops, and commercializes medicines for treating various diseases, including eye diseases, cancer, and infectious diseases.
3. When was Regeneron founded?
Regeneron was founded in 1988.
4. Who are the founders of Regeneron?
The founders of Regeneron are Leonard S. Schleifer and George D. Yancopoulos.
5. Where is Regeneron’s headquarters located?
Regeneron’s headquarters is located in Tarrytown, New York, USA.
6. What are some of Regeneron’s most well-known products?
Some of Regeneron’s most well-known products include EYLEA (aflibercept) for treating eye diseases, KEYTRUDA (pembrolizumab) for cancer, and REGEN-COV (casirivimab and imdevimab) for treating COVID-19.
7. How many employees does Regeneron have?
As of 2021, Regeneron has over 7,500 employees.
8. What is Regeneron’s stock symbol?
Regeneron’s stock symbol is REGN and it is listed on the NASDAQ stock exchange.
9. What is Regeneron’s mission statement?
Regeneron’s mission statement is “To improve the lives of patients with serious diseases, including those with cancer, eye diseases, and infectious diseases, through the development and commercialization of medicines.”
10. How does Regeneron approach drug discovery?
Regeneron uses a unique approach to drug discovery called “VelocImmune” which combines the power of VelocImmune mice with advanced technologies to rapidly identify and develop fully human antibodies for treating diseases.
